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Abstract: Background and Aims: Cases of Clostridioides difficile infection have been rising among
the pediatric and adolescent population. Fecal microbiota transplantation (FMT) has emerged as
an alternative therapy for recurrent C. difficile infection. We aim to perform the first systematic
review and meta-analysis investigating the safety and efficacy of fecal microbiota transplantation for
C. difficile infection in children and adolescents. Methods: A literature search was performed using
variations of the keywords “pediatrics”, “C. difficile infection”, and “fecal microbiota transplantation”
in PubMed, EMBASE, CINAHL, Cochrane, and Google Scholar from inception to 30 June 2022. The
resulting 575 articles were independently screened by three authors. Fourteen studies that satisfied
the eligibility criteria were included in the meta-analysis. Results: The pooled success rate of FMT
in the overall cohort was 86% (95% confidence interval: 77–95%; p < 0.001; I2 = 70%). There were
38 serious adverse events in 36 patients with a pooled rate of 2.0% (95% confidence interval: 0.0–3.0%;
p = 0.1; I2 = 0.0%) and 47 adverse events in 45 patients with a pooled rate of 15% (95% confidence
interval: 5.0–25.0%; p = 0.02; I2 = 54.0%). There was no death associated with FMT. Conclusions: FMT
was concluded to be an effective and safe therapy in pediatric and adolescent patients with C. difficile
infection. Underlying comorbidities may impede the efficacy. A rigorous screening process of the
donors is recommended prior to embarking on FMT. There is no universal and cost-effective way
to monitor the long-term outcomes of FMT. While promising, metagenomic sequencing may not be
available in settings with limited resources. Robust data from randomized clinical trials is warranted.
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1. Introduction
Clostridioides difficile (formerly Clostridium difficile) is a nosocomial infection that causes
severe watery diarrhea and is associated with increased hospitalization, healthcare costs,
morbidity, and mortality [1–3]. In the United States (U.S.) alone, C. difficile infection (CDI)
was responsible for half a million infections and over USD 1.5 billion in excess healthcare
expenditure in 2011 [3]. Approximately 20% of patients who were diagnosed with CDI in
2011 had a recurrence of CDI, which is defined as persistence of symptoms within 60 days
of completion of previous treatment [4]. Of those with recurrent CDI (rCDI), 29,000 patients
died from rCDI [4]. Originally thought to affect adults only, CDI has also been increasing
in its incidence among the pediatric population in both inpatient (hospital-acquired) and

Microorganisms 2022, 10, 2450. https://doi.org/10.3390/microorganisms10122450

https://www.mdpi.com/journal/microorganisms

Microorganisms 2022, 10, 2450

2 of 18

outpatient (community-acquired) settings over the past 20 years [4–7]. A 12.5-fold increase
in incidence of CDI was observed among the pediatric population from 1991 to 2009 [5,6].
Furthermore, up to 35% of pediatric patients may experience recurrence after treatment
with first-line agents [7]. The causes of recurrence include, but are not limited to dysbiosis
of the microbiome, continued exposure to C. difficile, and immunocompromised status [5].
Although there is a substantial amount of published data available for CDI in adults, CDI
in the pediatric population has been increasingly studied only in recent years. There is a
paucity of information on CDI in pediatric patients compared to their adult counterparts
with regard to the severity of the disease, the treatments available, the outcomes, and its
impact on the pediatric patients.
The traditional treatment of CDI includes antibiotics such as fidaxomicin, oral or rectal
vancomycin, and parenteral metronidazole as a single agent and/or in combination [1]. As
dysbiosis and reduced biodiversity of the gut microbiome has been noted among patients
with CDI or rCDI [6], fecal microbiota transplantation (FMT) has emerged in recent years as
an alternative therapy for rCDI [3]. The donor sample typically originates from adults and
can be attained through various preparations. For instance, the donor may be related to
the recipient, such as a family member, or unrelated [3]. In either case, it is paramount that
both donors and recipients undergo a screening process and have their stools analyzed for
microbiome composition prior to the procedure [3,7]. The sample itself may be collected as
a fresh specimen within 1–2 days prior to the transplantation or may be prepared from a
frozen donor stool from the stool bank [7]. FMT can be accomplished via different routes of
administration including, but not limited to, colonoscopy, capsules, and nasogastric tubes.
In adult patients, FMT has been demonstrated to be an effective therapy against CDI or
rCDI [1,5]. The first successful use of FMT in the pediatric population for CDI was reported
in the literature in 2010 [5]. In addition, FMT has been studied as a form of treatment in a
variety of pediatric conditions such as inflammatory bowel disease, autism spectrum, and
obesity [1–7]. Since 2010, several studies have investigated the effectiveness of FMT for the
treatment of CDI in adolescents and pediatric patients. In 2019, the North American Society
for Pediatric Gastroenterology, Hepatology and Nutrition, and the European Society for
Pediatric Gastroenterology, Hepatology, and Nutrition published a joint recommendation
that FMT may be used in pediatric patients with rCDI [8]. However, the long-term effects
(positive or negative) of alterations to the gut microbiome through FMT in the children
and adolescent population remain to be seen. Therefore, it was recommended that FMT be
performed only in experienced centers where the long-term effects could be monitored [8].
While FMT has been observed as an effective and safe therapy against CDI in children,
adolescents, and young adults, there are currently no randomized controlled trials published in the literature and the available information is derived from observational studies,
case series, and case reports [1–7,9,10]. Nonetheless, the current data from the literature
must be studied and analyzed for better elucidation of the available information. Therefore,
we aim to conduct the first systematic review and meta-analysis to determine the efficacy
and safety of FMT in the treatment of CDI and/or rCDI in the patients <18 years of age,
adolescents, and young adults.
2. Materials and Methods
2.1. Search Strategy
We performed a comprehensive literature search across five databases (Pubmed/Medline,
EMBASE, CINAHL, Cochrane, Web of Science, and Google Scholar) using variations of
the keywords “fecal microbiota transplant” and “pediatric” to identify original studies
published from inception through to 30 June 2022. Results were limited to human studies
published in English. There were a total of 575 studies for review.
Prior to screening the studies for eligibility to be included in the systematic review and
meta-analysis, our review was registered on PROSPERO (PROSPERO registration number
CRD42022343342; Registered 30 June 2022). See Supplemental Materials for detailed
search terms.
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2.2. Eligibility Criteria
Inclusion criteria were: (1) FMT for CDI and/or rCDI; (2) pediatric patients 21 years old
or younger; (3) reporting of patient data and outcomes after first fecal infusion; (4) patients
of any sex; (5) minimum follow-up of 2 months; (6) sample size of at least 5 patients; and
(7) at least moderate quality of evidence. In 2017, the American Academy of Pediatrics
defined adolescence from 12 to 21 years of age, and identified 21 years as the upper age
limit of the pediatric population [11]. Furthermore, several FMT studies on pediatrics
included age up to 21 years in the sample [5,12]. Therefore, patients of age up to 21 years
old were included in our systematic review and meta-analysis.
Exclusion criteria: (1) case reports with less than 5 patients; (2) published abstracts,
letters to editor, and commentaries which did not require detailed patient data or an
extensive review process; (3) studies without patient data; (4) non-English studies; and
(5) animal studies. Case series with more than 5 patients were included in our systematic
review and meta-analysis. The threshold for the number of patients that distinguished
between case series (5 or more patients) and case reports (less than 5 patients) was derived
from a prior concept analysis by Abu-Zidan et al. [13].
2.3. Quality Assessment
Newcastle–Ottawa Scale (NOS) is used to evaluate the methodological quality in
observational studies such as case-control and cohort studies. The risk of bias regarding the
selection of subjects, comparability of subjects, and assessment of the exposure and outcome
is graded by using a star system corresponding to nine items. A study is categorized as
low risk of bias if a total of 8 to 9 stars are allocated, medium risk of bias if 6 to 7 stars are
allocated, and high risk of bias if the study is given ≤5 stars [14].
For case series, the appraisal of quality and risk of bias was performed by a series of
quality assessment tools developed by the US National Heart Lung and Blood Institute
(NHLBI) of the National Institutes of Health (NIH, Bethesda, MD, USA) (https://www.
nhlbi.nih.gov/health-topics/study-quality-assessment-tools) (accessed on 1 August 2022).
Similar to the NOS, a set of question items with yes/no answers were used, with a “Yes”
counting as a score of 1 and a “No” as a score of 0. In this tool used for case series, there
were a total of 9 questions. A score of 7–9 corresponded to good quality, while scores of 4–6
and 1–3 indicated moderate and poor quality, respectively [14].
In the final selection stage, only studies with at least a moderate level of evidence were
included. Quality appraisal was performed by at least two of the following authors (K.M.T.,
C.H.L., T.L., and T.V.). If there was any disagreement, a senior reviewer (A.H.) evaluated
the article and achieved consensus through discussion. See Supplemental Materials for
quality assessment scores for each study.
2.4. Study Outcomes and Effect Size
The primary endpoint was the efficacy or clinical success of FMT in the treatment
of rCDI among the pediatric patient population. The term “success” was defined as the
resolution of symptoms (≥3 watery bowel movements in ≤24 h) and no requirement
for further interventions for CDI for at least 8 weeks after the date of FMT [1,4]. The
term “failure” or “recurrence” was used to describe an initial episode of CDI followed by
persistence of symptoms or return of symptoms that needed further treatment for CDI
within at least 8 weeks from the date of FMT [1,4,15]. Additionally, recurrence of CDI also
required positive laboratory testing, such as a nucleic acid amplification test or stool toxin
test in patients who remained symptomatic after FMT [1,15]. The effect size used in this
study was the event rate (success rate). The event or success rate was calculated by dividing
the number of reported events by the total sample size of the individual studies.
The secondary endpoint was the safety of FMT, which can be divided into serious
adverse events (SAE) and adverse events (AE) that occurred within at least 8 weeks after
FMT [15]. The SAEs and AEs were specifically labeled as attributable to FMT by the
respective authors from each study. If there was no specific delineation, it was assumed
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estimates of each study were pooled to compute the summary estimates
2.6. Data
Analysis
of the clinical success or efficacy of the FMT. A weighted summary statistic was calcuIndividual estimates of each study were pooled to compute the summary estimates
lated if many zero values occurred (e.g., adverse events) to prevent positive bias. The
of the clinical success or efficacy of the FMT. A weighted summary statistic was calculated
inverse variance heterogeneity (IVhet) model was fitted to account for methodological difif many zero values occurred (e.g., adverse events) to prevent positive bias. The inverse
ferences among the included studies for generating summary estimates [16]. The strength
of evidence of heterogeneity across studies was determined by Cochran’s Q and I2 statistics [17–19]. The values of under 30, 30–60, 61–75, and over 75% were categorized as
low, moderate, substantial, and considerable heterogeneity, respectively [20]). Subgroup
analyses of the clinical success of FMT by gender were also performed. Sensitivity analysis
was conducted to determine the validity of the estimated summary effect size. For the
sensitivity analysis, a “leave-one-out analysis” was conducted to investigate the impact
of the removal of study (one by one) on the estimates and LFK index asymmetry (Luis
Furuya-Kanamori index). Publication bias was assessed by visually inspecting funnel
plot and Doi plot [21,22]. In addition, Luis Furuya-Kanamori (LFK) index was used as a
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quantitative method to assess asymmetry of the study effects or publication bias as it has
been noted in the literature that LFK index has higher sensitivity than the Egger regression
statistics, particularly in meta-analysis with a small number of studies [21]. All metaanalyses were performed using MetaXL software (v. 5.3; EpiGear International, Sunrise
Beach, Queensland, Australia). The 95% Clopper–Pearson exact confidence intervals and
prediction intervals were calculated using R package [23,24].
3. Results
Table 1 summarizes the studies included in the systematic review and meta-analysis.
There was a total of 14 studies that comprised five retrospective observational studies, five
prospective observational studies, and four case series. In total, there were 904 pediatric
patients who received FMT. In Nicholson, 2022 [1], the total number of patients who
received FMT was 396, with success rates of 81.85% (203/248), 75.68% (112/148), and
79.55% (315/396), respectively, in the non-IBD, IBD, and overall cohorts. While efficacy was
reported for the overall sample cohort, the following data was reported only for IBD cohort:
gender, number of times of FMT administered, routes of FMT delivery, SAE, and AE.
Table 1. Summary of included studies.
Author/Year

Study
Design

Quality
Assessment

Score

Data
Collection
Period

Follow-Up
Period
(Months)

Number of
Patients Who
Received FMT

Single or
MultiCenter

Condition
Treated with
FMT

FMT Method

Nicholson
2022 [1]

Retrospective

NOS

8

03/2012–
03/2020

3

396

Multi-center

rCDI

Sigmoidoscopy/
Colonoscopy
Upper Gastrointestinal
Delivery *
Capsule

Li 2022 [2]

Retrospective

NOS

8

09/2014–
09/2020

3

29

Single

rCDI

Naso-intestinal
tube
Enema
Capsule

Prospective

NOS

7

02/2013–
12/2015

2

18

Single

rCDI

Colonoscopy
Enema
Nasogastric
tube

Aldrich
2019 [4]

Retrospective

NOS

9

01/2010–
12/2014

2

10

Single

rCDI

Colonoscopy
EGD
Nasojejunal
Gastric

Nicholson
2020 [5]

Retrospective

NOS

8

02/2004–
02/2017

3

335

Multi-center

Both CDI
and rCDI

Colonoscopy
Enteral routes
**

Hourigan
2019 [7]

Prospective

NOS

7

Not reported

6

9

Multi-center

rCDI

Colonoscopy

Barnes
2018 [9]

Prospective

NOS

8

06/2014–
06/2016

2.5

10

Single

rCDI

Colonoscopy
Upper Gastrointestinal
Delivery &

Fareed
2018 [10]

Prospective

NOS

8

Not reported

15

15

Multi-center

rCDI

Colonoscopy
Nasojejunal

Barfield
2018 [25]

Case series

NIH scale

9

10/2013–
11/2016

3

6

Single

Both CDI
and rCDI

Colonoscopy

Brumbaugh
2018 [26]

Retrospective

NOS

7

03/2015–
09/2016

3

42

Single

rCDI

Nasogastric or
gastrostomy
tube

Hourigan
2015 [27]

Prospective

NOS

7

Not reported

6

8

Multi-center

rCDI

Colonoscopy

Pierog
2014 [28]

Case series

NIH scale

7

Not reported

3

6

Single

rCDI

Colonoscopy

Kellermayer
2022 [3]
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Table 1. Cont.
Study
Design

Quality
Assessment

Score

Data
Collection
Period

Follow-Up
Period
(Months)

Number of
Patients Who
Received FMT

Single or
MultiCenter

Condition
Treated with
FMT

FMT Method

Kronman
2015 [29]

Case series

NIH scale

8

08/2011–
05/2014

6

10

Single

rCDI

Nasogastric,
nasojejunal or
nasoduodenal
tuve

Russell
2014 [30]

Case series

NIH scale

7

2009–2013

1 month to
48 months

10

Single

rCDI

Nasogastric
tube
Colonoscopy

Author/Year

NOS = Newcastle–Ottawa Scale; rCDI = recurrent Clostridioides difficile infection; CDI = Clostridioides difficile
infection; EGD = esophagogastroduodenoscopy; * Upper delivery includes esophagogastroduodenoscopy, nasoduodenal or nasojejunal delivery. ** Enteral routes of administration include nasogastric or gastrostomy tube,
nasoduodenal, nasojejunal, duodenal or jejunostomy tube. & Upper gastrointestinal delivery includes nasogastric,
jejunal, or jejunal route.

There were 326 male patients and 303 female patients from the studies that reported
the genders of those who received FMT. Three studies (Aldrich, 2019 [4], Hourigan, 2019 [7],
and Hourigan, 2015 [18]) did not distinguish the gender among the FMT patients. Nicholson, 2022 [1] reported gender data only for the IBD cohort as discussed above. The mean
age of patients was 9.38 ± 2.80 years. There were five multi-center studies and nine singlecenter studies. All studies were performed within the U.S.A (North America), except for
Li, 2022, [2] which was conducted in China (Asia). Almost all studies performed FMT for
rCDI except for Nicholson, 2020 [5] and Barfield, 2018 [25], where FMT was used for both
CDI and rCDI patients.
There were a total of 725 times FMT was administered since there were patients who
received FMT more than once. Table 2 demonstrates the various routes via which FMT
was administered. Delivery through the upper gastrointestinal tract included esophagogastroduodenoscopy, capsule, nasogastric, nasoduodenal, nasojejunal, gastric, duodenal, or
jejunostomy tubes. Delivery through the lower gastrointestinal tract included colonoscopy,
sigmoidoscopy, or enema. Colonoscopy was the most frequently used technique.
Table 2. Routes of FMT administration.
Route of FMT Administration

Number of Times FMT Administered (n = 725)

Nasogastric tube

85 (11.72%)

Naso-intestinal tube

36 (4.97%)

Nasoduodenal

1 (0.14%)

Nasojejunal tube

6 (0.83%)

Gastric tube

1 (0.14%)

Capsule

31 (4.28%)

Enema

20 (2.76%)

Both esophagogastroduodenoscopy and colonoscopy

1 (0.14%)

Sigmoidoscopy

2 (0.28%)

Colonoscopy

361 (49.79%)

Unspecified route via upper gastrointestinal tract

63 (8.69%)

Unspecified route via lower gastrointestinal tract

105 (14.48%)

Unspecified upper or lower gastrointestinal tract

13 (1.79%)

FMT = fecal microbiota transplantation.

Inflammatory bowel disease (IBD) was the most common concomitant disease, and
was found in 337 patients (Table 3). Other concurrent gastrointestinal diseases included
gastroesophageal reflux disease (n = 38), short bowel syndrome (n = 10), and celiac disease
(n = 1). Neuromuscular disorders included epilepsy, Lennox–Gastaut syndrome, Emmanuel
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syndrome, and muscular dystrophy, while genetic disorders such as mitochondrial disease,
and cystic fibrosis were also observed.
Table 3. Comorbidities found among the patients included in the systematic review and meta-analysis.
Comorbidities

Number of Patients

Inflammatory bowel disease (unspecified)

178

Ulcerative colitis

83

Crohn’s disease

76

Gastrointestinal diseases

49

Immunodeficient and/or transplant status

153

Malignancy

17

Neuromuscular disorders or impairment

8

Autism spectrum disorder

2

Genetic disorders

3

3.1. Primary Outcome
The primary outcome was the efficacy of FMT in treating CDI or rCDI. Success was
defined as the resolution of diarrhea symptoms (<3 watery bowel movements in ≤24 h)
without requiring further treatment or interventions for CDI for at least 8 weeks after
receiving FMT. Table 4 shows the number of patients who had success and those who had
failure with the treatment in the FMT cohort. The rate of success ranged between 66 and
100%, the latter of which was found in seven studies. The gross success rate was 81.86%
(740/904) while the overall failure rate was 18.14% (164/904).
Table 4. Efficacy outcomes in the FMT cohort.
Author/Year

Number of Patients Who
Received FMT

Number of Patients with
FMT Success (Percentage)

Number of Patients with
FMT Failure (Percentage)

Nicholson, 2022 [1]

396

315 (79.55%)

81 (20.46%)

Li, 2022 [2]

29

28 (96.55%)

1 (3.45%)

Kellermayer, 2022 [3]

18

12 (66.67%)

6 (33.33%)

Aldrich, 2019 [4]

10

10 (100%)

0 (0.00%)

Nicholson, 2020 [5]

335

271 (80.90%)

64 (19.10%)

Hourigan, 2019 [7]

9

9 (100%)

0 (0.00%)

Barnes, 2018 [9]

10

10 (100%)

0 (0.00%)

Fareed, 2018 [10]

15

15 (100%)

0 (0.00%)

Barfield, 2018 [25]

6

6 (100%)

0 (0.00%)

Brumbaugh, 2018 [26]

42

32 (76.19%)

10 (23.81%)

Hourigan, 2015 [27]

8

8 (100%)

0 (0.00%)

Pierog, 2014 [28]

6

6 (100%)

0 (0.00%)

Kronman, 2015 [29]

10

9 (90%)

1 (10.00%)

Russell, 2014 [30]

10

9 (90%)

1 (10.00%)

904

740 (81.86%)

164 (18.14%)

Total

FMT = fecal microbiota transplantation.

Table 5 further differentiates the FMT success cohort by gender. Some studies did not
report data on gender and are thus labeled as not reported (NR). The gross success rate was
78.98% (233/295) in males and 82.51% (217/263) in females. The failure rates were 21.02%
(62/295) and 17.49% (46/263) among male and female patients, respectively.
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Table 5. Efficacy outcomes by gender.

Author/Year

Number of Male
Patients with FMT
Success

Number of Female
Patients with FMT
Success

Number of Male
Patients with FMT
Failure

Number of Female
Patients with FMT
Failure

Nicholson, 2022 [1] **

63

49

21

15

Li, 2022 [2]

NR

NR

NR

NR

Kellermayer, 2022 [3]

6

6

4

2

Aldrich, 2019 [4]

NR

NR

0*

0*

Nicholson, 2020 [5]

136

135

36

28

Hourigan, 2019 [7]

NR

NR

0*

0*

Barnes, 2018 [9]

7

3

0

0

Fareed, 2018 [10]

6

9

0

0

Barfield, 2018 [25]

3

3

0

0

Brumbaugh, 2018 [26]

NR

NR

NR

NR

Hourigan, 2015 [27]

NR

NR

0*

0*

Pierog, 2014 [28]

4

2

0

0

Kronman, 2015 [29]

3

6

0

1

Russell, 2014 [30]

5

4

1

0

Total

233 (78.98%; 233/295)

217 (82.51%; 217/263)

62 (21.02%; 62/295)

46 (17.49%; 46/263)
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= fecal microbiota transplantation; NR = not reported. * While the results were not reported by 9gender,
Aldrich, 2019 [4], Hourigan, 2019 [7], and Hourigan, 2015 [27] reported 0 patients who failed FMT. ** Nicholson,
2022 [1] reported gender results only from the IBD cohort.
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Figure 2. Forest plot displaying clinical success or efficacy of FMT.
Figure 2. Forest plot displaying clinical success or efficacy of FMT.

Efficacy outcomes in the patients with IBD who received FMT are tabulated in Table 6.
Li, 2022 [2] and Aldrich, 2019 [4] did not differentiate the results for IBD patients. In Aldrich,
2019 [4], it was noted that 14% of the 175 subjects had known or were later diagnosed
with IBD, the number of which was approximated to 25. In Nicholson, 2020 [5], out of the
120 IBD patients, only 111 had data available regarding FMT. In Barfield, 2018 [25], one
patient required an additional delivery of FMT after 3 months from initial FMT due to the
recurrence of symptoms and achieved resolution of CDI thereafter. In Brumbaugh, 2018 [26],

(95% confidence interval [CI]: 77%, 95%; p < 0.001; I = 70%). Figure 2 shows the forest plot
for clinical success or the efficacy of FMT. By gender, the calculated pooled rate of clinical
success of FMT was 81% among males (95% confidence interval [CI]: 71%, 91%; p = 0.1; I2
= 40%) as opposed to an 84% success rate among their female counterparts (95% confidence interval [CI]: 78%, 90%; p = 0.4; I2 = 10%) as shown in Figure 3.
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one IBD patient required FMT twice for success while one patient still had persistent CDI
despite also receiving FMT twice. In Russell, 2014 [30], one patient continued to experience
gastrointestinal symptoms but remained negative on enzyme immunoassay (EIA) for CDI.
The patient’s symptoms improved after initiating treatment for Crohn’s disease. That
patient was counted as a success. There was one patient who was lost to follow up after
2 months and was counted as a failure. The overall success rate of FMT for CDI in IBD
patients was 75.33% (223/296) while the failure rate was 24.66% (73/296). Although the
total number of patients in the IBD cohort was 337, since there were two studies that did
not report results for IBD patients, the numbers of patients from those studies were not
included
in calculating
the overall
failureofrates.
Figure
2. Forest
plot displaying
clinicalsuccess
success and
or efficacy
FMT.

Figure 3. Forest plot displaying clinical efficacy of FMT by gender.
Figure 3. Forest plot displaying clinical efficacy of FMT by gender.

Efficacy outcomes
3.2. Secondary
Outcome in the patients with IBD who received FMT are tabulated in Table
6. Li, The
2022secondary
[2] and Aldrich,
2019
[4]serious
did notadverse
differentiate
results
for IBD events
patients.
In
outcomes
were
eventsthe
(SAE)
and adverse
(AE).
Aldrich,
2019
[4],
it
was
noted
that
14%
of
the
175
subjects
had
known
or
were
later
diagAmong the SAE and AE reported from the studies, only those that were determined to
nosed
with IBD,to
theFMT
number
of respective
which wasstudies
approximated
to 25. IninNicholson,
2020 [5],
out
be attributable
by the
were included
our systematic
review
ofand
themeta-analysis.
120 IBD patients,
only
111
had
data
available
regarding
FMT.
In
Barfield,
2018
[25],
Most studies documented SAE and AE within 3 months after the
one
patient required
anFMT,
additional
delivery
FMT afterthe
3 months
fromperiods
initial FMT
due to
administration
of the
except
for theof
following:
follow-up
of Aldrich,
the
recurrence
of symptoms
and achieved
resolution
of CDI
thereafter.while
In Brumbaugh,
2019
[4] and Barnes,
2018 [9] were
2 months and
2.5 months,
respectively,
one patient
2018
[26], one
IBD
patient
required
FMT twice
success while one patient still had perin Russell,
2014
[30]
was lost
to follow-up
afterfor
4 months.
sistentThere
CDI despite
FMTand
twice.
In Russell,
2014 [30],
one patient
continued
were 38 also
SAEreceiving
in 36 patients
47 AE
in 45 patients
as shown
in Table
7. There
to
experience
gastrointestinal
symptoms
but
remained
negative
on
enzyme
immunoassay
was no death attributable to FMT. The causes of SAE were variable and there was no single
(EIA)
for CDI. cause.
The patient’s
symptoms
improved
afterSAE
initiating
treatment
for [1],
Crohn’s
predominant
While there
were 20
IBD-related
in Nicholson,
2022
SAE disand
ease.
Thatreported
patient was
as a cohort
success.and
There
onenon-IBD
patient who
was
lost to the
follow
AE were
onlycounted
for the IBD
not was
for the
cohort.
Among
AE,
up
after 2 and
months
and waspain
counted
a failure. recorded.
The overall success rate of FMT for CDI in
diarrhea
abdominal
were as
commonly
The calculated
pooled
rate of serious
adverse
was24.66%
2.0% (95%
confidence
interval
IBD patients
was 75.33%
(223/296)
while the
failureevents
rate was
(73/296).
Although
the
[CI]:number
0.0%, 3.0%;
p = 0.1;
I2 =IBD
0.0%),
andwas
the337,
pooled
of were
adverse
total
of patients
in the
cohort
sincerate
there
two events
studieswas
that 15%
did
(95% confidence interval [CI]: 5.0%, 25.0%; p = 0.02; I2 = 54.0% as shown in Figure 4. Based
on the validation analysis (described below), Nicholson, 2022 [1] and Nicholson, 2020 [5]
were discovered to have dominant effects on the analysis. Therefore, Nicholson, 2022 [1]
was removed from analyses for both SAE and AE, while Nicholson, 2020 [5] was removed
from the forest plot for AE (Figure 4).
3.3. Validation Analysis (Leave-One-Out Analysis)
To assess if any study involved in the main analysis had a dominant effect, a leave-oneout analysis was conducted. As shown in Table 8, upon removal of each study one by one,
no significant impact on the summary statistics of the primary outcome or heterogeneity
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was found. However, in the analysis of the secondary outcomes, one study in both SAE
and AE (Nicholson, 2022) and one in AE (Nicholson, 2020) had dominant effects on the
summary statistics, which were excluded from the analysis. These studies were removed
from forest plot analysis for SAE and AE.
Table 6. Efficacy outcomes by IBD.
Author/Year

Total Number of IBD
Patients Who Received FMT

Number of IBD Patients
with FMT Success

Number of IBD Patients
with FMT Failure

Nicholson, 2022 [1]

148

112

36

Li, 2022 [2]

16

NR

NR

Kellermayer, 2022 [3]

5

1

4

Aldrich, 2019 [4]

25

NR

NR

Nicholson, 2020 [5]

120 **

85

26

Hourigan, 2019 [7]

0

N/A

N/A

Barnes, 2018 [9]

0

N/A

N/A

Fareed, 2018 [10]

5

5

0

Barfield, 2018 [25]

2

2

0

Brumbaugh, 2018 [26]

13

7

6

Hourigan, 2015 [27]

5

5

0

Pierog, 2014 [28]

1

1

0

Kronman, 2015 [29]

3

3

0

Russell, 2014 [30]

3

2

1

Total

346

223 (75.33%; 223/296) *

73 (24.66%; 73/296) *

IBD = inflammatory bowel disease; FMT = fecal microbiota transplantation; NR = not reported; N/A = not
applicable; * Since Li, 2022 [2] and Aldrich, 2019 [4] did not delineate outcomes for IBD patients, the number of
patients from those studies were not included in calculating the rates of success or failure. ** Similarly, while
there were 120 IBD patients who received FMT in Nicholson, 2020 [5], only 111 patients had their outcomes
reported. Since the results of the remaining 9 patients were unknown, they were not included in assessing success
or failure rates.

Table 7. Serious adverse events and adverse events.
Number of SAEs
Related to FMT

Description of SAE

Number of Patients
with SAE

Number of AE
Related to FMT

Description of AE

Number of
Patients with AE

Nicholson,
2022 [1]

29

19 IBD-related
hospitalization;
1 pancreatitis-related
hospitalization;
9 IBD-related surgeries

27

NR

NR

NR

Li 2022 [2]

0

N/A

0

4

1 fever;
1 transient diarrhea,
1 transient abdominal
pain;
1 vomit

4

Kellermayer,
2022 [3]

0

N/A

0

2

1 paradoxical diarrhea
1 intermittent diarrhea
and abdominal pain

2

Aldrich,
2019 [4]

NR

NR

NR

NR

NR

NR

Nicholson,
2020 [5]

7

1 aspiration pneumonia;
3 IBD flare;
2 colectomy;
1 vomiting and
dehydration

7

19 *

Diarrhea
Abdominal pain
Vomiting

19

Hourigan,
2019 [7]

0

N/A

0

1

Chronic diarrhea and
fecal urgency of
non-infectious etiology

1

Author/Year
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Table 7. Cont.
Author/Year

Number of SAEs
Related to FMT

Description of SAE

Microorganisms
Barnes, 2018 [9] 2022, 10, x 0FOR PEER REVIEW N/A

Number of Patients
with SAE

Number of AE
Related to FMT

Description of AE

0

NR

NR
5 abdominal pain

5

N/A

0

Fareed,
2018 [10]

0

N/A

0

5

Barfield,
2018 [25]

0

N/A

0

0

Brumbaugh,
2018 [26]

0

N/A

0

6

Hourigan,
2015 [27]

0

N/A

0

1

Pierog,
2014 [28]

2

1 appendicitis
1 infection unrelated to
gastrointestinal
N/Atract

2

36

0

47

1 diarrhea with
abdominal
pain;
6 vomiting
2 bloody
stools
Diarrhea of
non-infectious
etiology
with
bloating
and
abdominal pain
N/A
N/A

Number of
Patients with AE
NR12 of 19

6
1

0

Total

38

45

Kronman,
2015 [29]

0

1 vomiting
IBD = inflammatory
bowel disease;
NR = not reported;
N/A = not applicable;
* Nicholson,1 2020 [5]
N/A
0
2
1 mucoid stools
did not report the specific number of each AE.

Russell,
2014 [30]

0

1 mucoid stools;
3 abdominal pain and
The calculated pooled rate of serious adverse events wasdiarrhea;
2.0% (95% confidence inter1 diarrhea with
6 (95%
val [CI]:N/A
0.0%, 3.0%; p = 0.1; I02 = 0.0%), and the7pooled rate ofabdominal
adverse
events was 15%
pain;
2
2
bloody
stools
with
confidence interval [CI]: 5.0%, 25.0%; p = 0.02; I = 54.0% as shown in Figure 4. Based on
bloating and abdominal
the validation analysis (described below), Nicholson, 2022 [1]
painand Nicholson, 2020 [5]

Total

38

were discovered
to have dominant
effects on47the analysis. Therefore,
Nicholson,452022 [1]
N/A
36
N/A
was
removed
from
analyses
for
both
SAE
and
AE,
while
Nicholson,
2020
[5] was
IBD = inflammatory bowel disease; NR = not reported; N/A = not applicable; * Nicholson, 2020
[5] didremoved
not report
the specific
numberplot
of each
from
the forest
forAE.
AE (Figure 4).

Figure
and adverse
adverse events
events of
of FMT.
FMT.
Figure 4.
4. Forest
Forest plot
plot displaying
displaying pooled
pooled rates
rates of
of serious
serious adverse
adverse events
events and

3.3. Validation Analysis (Leave-One-Out Analysis)
To assess if any study involved in the main analysis had a dominant effect, a leaveone-out analysis was conducted. As shown in Table 8, upon removal of each study one by
one, no significant impact on the summary statistics of the primary outcome or heterogeneity was found. However, in the analysis of the secondary outcomes, one study in both
SAE and AE (Nicholson, 2022) and one in AE (Nicholson, 2020) had dominant effects on
the summary statistics, which were excluded from the analysis. These studies were removed from forest plot analysis for SAE and AE.
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Table 8. Outputs of sensitivity analysis (n = 14).
Studies

Pooled ES

LCI 95%

UCI 95%

Cochran Q

p

I2

I2 LCI 95%

I2 UCI 95%

Nicholson, 2022 [1]

0.876

0.777

0.976

34.999

0.000

65.713

38.297

80.947

Li, 2022 [2]

0.845

0.747

0.943

37.581

0.000

68.069

43.107

82.079

Kellermayer, 2022 [3]

0.861

0.769

0.952

41.218

0.000

70.887

48.797

83.447

Aldrich, 2019 [4]

0.853

0.760

0.946

40.570

0.000

70.422

47.863

83.220

Nicholson, 2020 [5]

0.894

0.811

0.978

35.512

0.000

66.208

39.312

81.184

Hourigan, 2019 [7]

0.853

0.760

0.947

41.123

0.000

70.820

48.662

83.414

Barnes, 2018 [9]

0.853

0.760

0.946

40.570

0.000

70.422

47.863

83.220

Fareed, 2018 [10]

0.847

0.755

0.939

36.915

0.000

67.493

41.935

81.801

Barfield, 2018 [25]

0.855

0.763

0.948

42.451

0.000

71.732

50.490

83.860

Brumbaugh, 2018 [26]

0.862

0.766

0.958

41.983

0.000

71.417

49.860

83.706

Hourigan, 2015 [27]

0.854

0.761

0.947

41.616

0.000

71.165

49.355

83.583

Pierog, 2014 [28]

0.855

0.763

0.948

42.444

0.000

71.728

50.481

83.858

Kronman, 2015 [29]

0.857

0.762

0.952

43.802

0.000

72.604

52.227

84.289

Russell, 2014 [30]

0.857

0.762

0.952

43.802

0.000

72.604

52.227

84.289

ES = effect size; LCI = lower confidence interval; UCI = upper confidence interval.

4. Discussion
To our best knowledge, this is the first systematic review and meta-analysis of the
safety and efficacy of FMT via all routes of administration in treating CDI and rCDI
amongst pediatric patients. A prior systematic review by Iqbal et al., in 2018 demonstrated
the effectiveness of encapsulated FMT to treat rCDI in patients of all ages [31]. The overall
success rate from that systematic review was 92.6% (316/341); the overall success rate
from our meta-analysis was 81.86% (740/904). The discrepancy in the efficacy can be
explained by several factors. Firstly, Iqbal et al., included patients from all ages and there
was only one study that consisted of data solely from pediatric patients [31,32]. Moreover,
the review focused on FMT delivered via capsules only. On the other hand, our review
focused solely on pediatric and adolescent patients up to and including the age of 21 and
FMT administered via any route. These variables could have accounted for the difference
in efficacy. Indeed, studies have concluded that encapsulated FMT may be considered in
adult patients who previously failed to achieve resolution of CDI by other methods of FMT
delivery such as colonoscopy [31,33,34]. A prior systematic review by Iqbal et al., concluded
that encapsulated FMT was similar in efficacy and was associated with fewer adverse events
when compared to colonoscopy [31]. In the same study, 8 out of 10 patients who previously
failed FMT with colonoscopy achieved resolution of rCDI with encapsulated FMT [31].
Furthermore, routes such as colonoscopy, enema, nasogastric, or nasoduodenal tubes have
been demonstrated to be inconvenient for patients [33], while oral preparation has been
associated with greater ease of administration [34].
Our study confirmed a pooled success rate of 86% (95% CI: 77–95%, p < 0.001). Hence,
FMT may still be used as an effective treatment for rCDI in pediatric patients. In fact, based
on the success rate reported in the literature for the pediatric patient population, Infectious
Diseases Society of America (IDSA) recommended, in 2017, that FMT may be considered
in those who continued to experience multiple recurrences of CDI despite treatment with
standard antibiotics [35,36].
However, despite its efficacy, FMT still remains relatively poorly regulated and standardized [36]. As discussed above, the routes of FMT administration may impact its effectiveness. Comorbidities and the gut microbiome composition of the recipient or the donor
may also interfere with its therapeutic potential and may also be associated with adverse
outcomes. In addition to the variabilities in success rate, since the delivery of FMT often
requires a procedure such as colonoscopy, esophagogastroduodenoscopy, or use of enteral
tubes, it also carries procedure-related risks [35]. The most common adverse outcomes from
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our review were diarrhea and abdominal pain or discomfort. The findings were consistent
with the results previously reported in the literature for both adults and pediatrics [31,36].
Concerns have also been raised regarding SAE, such as transmission of multi-drug resistant
organisms (MDRO), and blood-borne infections [35]. In 2019, the United States Food and
Drug Administration released a safety alert and recommendations for more comprehensive
screening and testing of the donors after two immunocompromised adult patients received
FMT from a donor with positive extended-spectrum beta-lactamase (ESBL) producing
Escherichia coli [36]. Both patients developed the infection and one subsequently expired.
In our review, the rate of SAE and AE was low overall. The pooled rate for SAE was
2.0% (95% CI: 0.0–3.0%, p = 0.1) and the pooled rate for AE was 15% (95% CI: 5.0–25.0%,
p = 0.02). The pooled rate for AE was slightly higher but comparable to the 12.5% that
was derived from a systematic review of adult FMT patients by Iqbal et al. [31]. We also
did not identify any deaths attributable to FMT, similar to the results by Iqbal et al., [31].
Furthermore, there was no infection caused by an MDRO after receiving FMT. Nonetheless,
the causative pathogens from the aspiration pneumonia, appendicitis, or the infection
unrelated to the gastrointestinal tract, which were part of SAE in our meta-analysis, were
not known. It is also unclear whether the IBD-related hospitalizations or exacerbations
were related to an infection episode. Moreover, viral RNA of SARS-CoV-2 has been
found in the feces of infected patients [37]. Although there has not yet been documented
transmission of COVID-19 via feces, the FDA recommended screening for the virus in
potential donors [36]. Taking everything into consideration, we concur that donors should
undergo a comprehensive screening process for infectious agents, including COVID-19,
prior to the transplantation. While FMT has been successfully used to decolonize adult
patients with MDROs, the available data is limited for similar use in pediatric patients and
further research is warranted [38].
It is worth noting that both the recommendation from the FDA and the onset of the
COVID-19 pandemic have led to changes not only in the practice of FMT administration
but also the availability and access of FMT for pediatric patients [39]. For instance, the FDA
also limited use of FMT to only emergent situations in 2020 and early 2021 during the peak
of the COVID-19 pandemic [39]. A survey of pediatric gastroenterologists also showed that
some practitioners took additional precautions such as increased screening of the donors
or avoidance of FMT in immunocompromised patients. Some physicians increased the
utilization of antibiotics such as fidaxomicin and oral vancomycin, while others entirely
paused the program [39].
Dysbiosis has been established among IBD patients [40]. The success rate for FMT for
CDI in pediatric patients with IBD from our review was 75.00% and was effective but was
lower than the pooled success rate of 86.00%. The results were similar to prior observational
studies such as Nicholson, 2022 [1], where the efficacy rates for overall, IBD, and nonIBD cohorts were 79.55, 75.68, and 81.85%, respectively. Nevertheless, Nicholson et al.,
concluded that there was no difference in FMT success between children with IBD and
without IBD [1]. However, the authors discovered that a high proportion of children
with FMT failure was found among those with clinically active IBD [1]. There are several
confounding variables that can potentially influence the outcomes of FMT for CDI among
IBD patients. Some examples include the type of stool received (e.g., fresh versus frozen
stools), time from diagnosis of CDI until FMT, severity of CDI or IBD symptoms, mode
of delivery, and concomitant medications, among others [1,40]. A systematic review and
meta-analysis by Tariq et al. concluded that FMT is an effective therapy for rCDI in adult
patients with IBD [41]. A similar analysis for pediatric patients has not been completed to
the best of our knowledge.
Lastly, FMT has been associated with the restoration of the gut microbiome in CDI
patients to the levels of healthy children [3]. Since the patients are at an age where the gut
microbiome is still undergoing development at the time of receiving FMT, manipulation
of the microbiome may influence metabolic or immune dysregulations [36]. In particular,
restoration was noted in the levels of Lachnospiraceae, Ruminococcaceae, Bifidobacteriaceae,
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Erysipelotrichaceae, and Bacteroidaceae, the latter of which has been believed to be a key
protective member of the gut microbiota [3]. Decolonization of Enterobacteriaceae, which
can remain abundant in treatment-naive CDI patients prior to FMT, was also observed [3].
In other words, metagenomics may be a potential modality to predict long-term outcome
of FMT in pediatric patients with rCDI. However, the presence of comorbidities such
as IBD, immunocompromised status, or neurologic conditions may impede the process
of reconstituting the gut microbiome and can result in the failure of FMT or requiring
multiple administration of FMT [3]. The cost of metagenomic sequencing also presents
a practical barrier to be performed in every patient receiving FMT. Thus, metagenomic
sequencing of the gut microbiome may not be used as a predictor of long-term outcome
in pediatric patients with complicated background comorbidities and/or in settings with
limited resources [3].
Limitations
We acknowledge several limitations. First, there were no randomized controlled trials
in the previously published literature to include in our meta-analysis. Second, two studies
needed to be excluded from the secondary outcome analysis to avoid a predominant effect
on the analysis. Third, given that this is a systematic review and meta-analysis, we were not
able to control for confounding variables in the patient qualities or the procedural protocols.
Moreover, the determination of whether SAE or AE were attributable to FMT was made by
the original authors. Since we were unable to review the original data of the studies, it is
possible that the number of SAE or AE related to FMT may not accurately reflect the true
Microorganisms 2022, 10, x FOR PEER REVIEW
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number of adverse events. Fourth, there was evidence of publication bias present as shown
by the Doi plot in Figure 5, Funnel plot in Figure 6, and an LFK index of greater than 4.

Figure 5. Doi plot for assessing the evidence of publication bias.
Figure 5. Doi plot for assessing the evidence of publication bias.

Lastly, we did not include Cho, 2019 [42] in our meta-analysis. The efficacy rate
reported by Cho et al., was 75% from eight patients [42], which was comparable to that of
the overall cohort of 904 patients (86%) and the IBD cohort of 296 patients (75.33%) from
our meta-analysis. In addition, there was one SAE from Cho, 2019 [42] with abdominal
pain and fever that was ultimately concluded to be related to influenza and not to FMT
by the original authors. There were no other SAE or AE attributable to FMT from Cho,
2019 [42]. Therefore, while the study was not included in the meta-analysis, the impact was
determined to be negligible in the current meta-analysis.
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Figure 5. Doi plot for assessing the evidence of publication bias.

Figure 6. Funnel plot for assessing the evidence of publication bias.
Figure 6. Funnel plot for assessing the evidence of publication bias.
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